SMS Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SMS Pharmaceuticals Limited has filed copies of newspaper advertisements containing its unaudited standalone and consolidated financial results for the quarter ended 30 June 2025. The results were published in The Financial Express (English) and Andhra Prabha (Telugu) on 10 August 2025, as required under SEBI LODR Regulations 33 and 47, and are also available on the company's website. The Board had approved the results at its meeting held on 9 August 2025. From the published extract, standalone revenue from operations rose to about Rs. 196.64 crore in Q1 FY26 from Rs. 165.82 crore in Q1 FY25, a growth of roughly 18.6% year-on-year. Standalone profit after tax improved to about Rs. 24.37 crore from Rs. 21.83 crore, up about 11.6% year-on-year, with diluted EPS of Rs. 5.27 for the quarter.
This is a routine regulatory filing of already-disclosed quarterly results in newspapers, so the stock price impact is likely limited. However, the underlying numbers show healthy double-digit growth in both revenue and profit, which is a positive signal for shareholders.